Life Care Center of Merrimack Valley: Consent Failures - MA
The violations involved antipsychotic drugs, antidepressants and anxiety medications administered to newly admitted residents starting August 12. Staff didn't secure consent forms until August 14, the day inspectors arrived.
Resident #1 received three different psychiatric drugs without consent. The person was admitted in August with diagnoses including chronic kidney disease, depression and anxiety disorder. Physician orders called for Fluoxetine, an antidepressant, plus Hydroxyzine and Trazodone for anxiety and sleep.
Medication records showed the resident received one dose of Fluoxetine and two doses each of Hydroxyzine and Trazodone before consent was obtained.
A second resident faced more extensive medication exposure. Admitted in August with major depressive disorder, bipolar disorder and psychotic disorder, this person received orders for four psychiatric medications starting August 12.
The regimen included Bupropion XL 300 mg daily for depression, Haloperidol 10 mg at bedtime for psychotic disorders, Hydroxyzine 25 mg at bedtime, and Sertraline 200 mg at bedtime for depression.
Records showed staff administered one dose of Bupropion and two doses each of Haloperidol and Sertraline before securing consent three days later.
The third resident, admitted with chronic obstructive pulmonary disease, anxiety disorder, chronic respiratory failure and emphysema, received multiple anxiety medications without consent.
Orders dated August 12 included Lorazepam 0.5 mg every eight hours as needed for anxiety, plus Olanzapine 2.5 mg twice daily and every six hours as needed for anxiety.
The resident received three doses of Lorazepam and four doses of Olanzapine before consent was obtained August 14.
During an interview on August 14 at 4:58 PM, the Director of Nurses acknowledged the systematic consent failures.
She confirmed no informed consent was obtained for Resident #1's Fluoxetine, Hydroxyzine and Trazodone during admission. For Resident #2, she said consent for Bupropion XL, Haloperidol, Hydroxyzine and Sertraline was not obtained upon admission or prior to administration.
The Director of Nurses made the same admission regarding Resident #3's Lorazepam and Olanzapine.
She told inspectors the facility expects nurses admitting each resident to obtain informed written consent for psychotropic medications from either the resident or their responsible party before administering any psychiatric drugs.
The medications involved carry significant risks and side effects. Haloperidol, an antipsychotic, can cause movement disorders and other serious reactions. Lorazepam, a benzodiazepine, carries risks of dependency and cognitive impairment, particularly dangerous for elderly residents.
Olanzapine, another antipsychotic, can cause weight gain, diabetes and movement problems. The combination of multiple psychiatric drugs without proper consent documentation represents a serious breach of patient rights.
Federal regulations require nursing homes to obtain informed consent before administering psychotropic medications. The consent process ensures residents or their representatives understand the medication's purpose, risks and alternatives.
All three residents were newly admitted in August 2025, suggesting the consent failures occurred during the facility's admission process. The violations affected residents with serious underlying conditions including depression, anxiety disorders, psychotic disorders and chronic respiratory problems.
The timing of the consent forms, obtained only when inspectors arrived, raises questions about whether staff would have secured proper authorization without regulatory oversight.
Inspectors classified the violations as causing minimal harm or potential for actual harm to some residents. However, the administration of psychiatric medications without consent represents a fundamental violation of patient autonomy and informed decision-making.
The systematic nature of the consent failures across three separate admissions indicates potential problems with the facility's admission procedures and staff training on psychotropic medication requirements.
Each resident received multiple doses of psychiatric medications before any consent was documented, suggesting the problem persisted over several days without detection or correction by facility management.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Life Care Center of Merrimack Valley from 2025-08-14 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: June 20, 2026 · Our methodology
LIFE CARE CENTER OF MERRIMACK VALLEY in BILLERICA, MA was cited for violations during a health inspection on August 14, 2025.
The violations involved antipsychotic drugs, antidepressants and anxiety medications administered to newly admitted residents starting August 12.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.